-
公开(公告)号：EP4441028A1
公开(公告)日：2024-10-09
申请号：EP24703833.4
申请日：2024-01-26
发明人： JOSEPH, Melissa , LAWRENCE, Ronnie Maxwell , MORTEN, Elaine , CHITRE, Saurabh , KELK, Natalie Louise , CALLAHAN, Craig
IPC分类号： C07C217/34 , A61K31/045 , A61P9/00 , A61P21/00 , A61K31/04
CPC分类号： C01B25/26 , C07B2200/1320130101 , C07C217/34 , A61P21/00 , A61P9/00 , A61K31/138 , C01P2002/7220130101 , C01P2006/3420130101
-
-
3.发明公开
公开(公告)号：EP4440569A1
公开(公告)日：2024-10-09
申请号：EP22823465.4
申请日：2022-11-30
申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) , Centre National de la Recherche Scientifique , Université Côte d'Azur , Centre Hospitalier Régional , Association Française contre les Myopathies (A.F.M.)
IPC分类号： A61K31/345 , A61P25/28 , A61P9/00 , A61P21/00
CPC分类号： A61K31/345 , A61P25/28 , A61P9/00 , A61P21/00
-
公开(公告)号：EP4093427B1
公开(公告)日：2024-10-09
申请号：EP20717600.9
申请日：2020-04-02
CPC分类号： A61K38/2242 , A61P9/00
-
公开(公告)号：EP3512937B1
公开(公告)日：2024-10-09
申请号：EP17851425.3
申请日：2017-09-13
IPC分类号： C12N5/079 , C12N5/0797 , C12N15/09 , C12N15/861 , A61K48/00 , A61K35/13 , A61K35/30 , C07K14/005 , C07K14/075
CPC分类号： A61K35/13 , A61K35/30 , C07K14/005 , A61K35/44 , A61L27/3808 , A61L27/3878 , A61L27/3886 , C12N2710/1032220130101 , A61P25/00 , A61P43/00 , A61P9/00
-
公开(公告)号：EP4438621A2
公开(公告)日：2024-10-02
申请号：EP24181690.9
申请日：2015-08-05
发明人： MALEK, Thomas
IPC分类号： C07K14/55
CPC分类号： A61K38/00 , C07K14/7155 , C07K2319/0020130101 , C07K2319/2120130101 , C07K14/55 , A61P1/00 , A61P1/04 , A61P1/12 , A61P17/06 , A61P17/14 , A61P19/02 , A61P21/00 , A61P25/00 , A61P29/00 , A61P31/14 , A61P35/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P43/00 , A61P9/00 , A61P3/10
摘要： Various methods and compositions are provided which can be employed to modulate the immune system. Compositions include a fusion protein comprising: (a) a first polypeptide comprising Interleukin-2 (IL-2) or a functional variant or fragment thereof, and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL-2Rα ) or a functional variant or fragment thereof, and wherein the fusion protein has IL-2 activity. Various methods are provided for modulating the immune response in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the IL-2/IL-2Rα fusion protein disclosed herein.
-
公开(公告)号：EP4438040A1
公开(公告)日：2024-10-02
申请号：EP22864522.2
申请日：2022-08-30
申请人： Japan Tobacco Inc.
IPC分类号： A61K31/424 , A61K31/437 , A61K31/4985 , A61K31/5377 , A61K31/5386 , A61P3/00 , A61P3/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P21/00 , A61P25/00 , A61P25/02 , A61P25/28 , A61P35/00 , A61P43/00 , C07D498/04 , C07D519/00
CPC分类号： A61K31/424 , A61K31/437 , A61K31/4985 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61P3/00 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P21/00 , A61P25/28 , A61P25/00 , A61P25/02 , A61P27/06 , A61P35/00 , A61P43/00 , C07D471/14 , C07D487/14 , C07D498/04 , C07D498/14 , C07D519/00
摘要： The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary diseases, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension, Alzheimer disease, vascular dementia, glaucoma, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, ischemic optic neuropathy or chronic kidney disease. The present invention relates to a compound of the formula [I], the formula [II] or the formula [III], or a pharmaceutically acceptable salt thereof:
wherein each symbol is as defined in the DESCRIPTION.-
公开(公告)号：EP4436968A1
公开(公告)日：2024-10-02
申请号：EP22843901.4
申请日：2022-11-07
发明人： BEVERIDGE, Ramsay , BURCH, Jason , FADER, Lee , BOILY, Marc-Olivier , ST-ONGE, Miguel , DORICH, Stéphane , CHAGNON, Felix , DURET, Guillaume
IPC分类号： C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D498/04 , C07D513/04 , A61P3/00 , A61P9/00 , A61P11/00 , A61P13/12 , A61P17/00 , A61P25/00 , A61P25/16 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/00 , A61P37/00
CPC分类号： C07D417/12 , C07D417/14 , C07D498/04 , C07D513/04 , C07D487/04 , C07D471/04 , A61P35/00 , A61P29/00 , A61P37/00 , A61P31/00 , A61P25/00 , A61P3/00 , A61P9/00 , A61P11/00 , A61P13/12 , A61P27/02 , A61P17/00 , A61P25/16 , A61P25/28
-
公开(公告)号：EP4436951A1
公开(公告)日：2024-10-02
申请号：EP22899230.1
申请日：2022-11-16
发明人： ASLAN, Mutay Aydin , BASRALI, Filiz , ULKER, Pinar
IPC分类号： C07C237/22 , A61P9/00
CPC分类号： A61P9/00
-
公开(公告)号：EP4417261A3
公开(公告)日：2024-10-02
申请号：EP24168584.1
申请日：2017-04-19
发明人： NEVILLE, Anne , BROWNE, Hilary , FORSTER, Sam , LAWLEY, Trevor
IPC分类号： A61K35/742 , A61P31/04
CPC分类号： A61K35/742 , A61P1/00 , A61P1/04 , A61P1/16 , A61P11/06 , A61P19/02 , A61P25/00 , A61P25/16 , A61P25/28 , A61P3/00 , A61P3/04 , A61P31/04 , A61P35/00 , A61P3/06 , A61P37/02 , A61P37/08 , A61P43/00 , A61P7/00 , A61P9/00 , A61P3/10 , Y02A50/30
摘要： The invention relates to therapeutic compositions comprising at least one isolated bacterium and a pharmaceutically acceptable excipient, as well as methods of preparing such therapeutic compositions. The therapeutic compositions find application in the treatment of dysbiosis, in particular dysbiosis of the gastrointestinal tract.
-
-
-
-
-
-
-
-
-
搜索结果
497 条记录 (耗时 0.021 秒)
